Wed.May 22, 2024

article thumbnail

Pfizer, busy with $4B savings drive, plots even more cuts out to 2027

Fierce Pharma

Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. | Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. Now, the company has unveiled another savings drive that will run longer.

317
317
article thumbnail

5 Things to Know About the Sorry State of Healthcare Cybersecurity

MedCity News

During a fireside chat at MedCity News’ INVEST conference, Nitin Natarajan — deputy director at the Cybersecurity and Infrastructure Security Agency (CISA) — shared some key ideas that people need to understand about the current state of cybersecurity in the healthcare industry. For instance, he reminded us that things won’t get better overnight, and that cybersecurity requires an all-hands-on deck approach.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Otsuka pulls plug on Alzheimer's agitation drug after 2nd failed trial

Fierce Pharma

Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on m | Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on measures of agitation associated with dementia.

article thumbnail

GSK’s twice-yearly asthma drug clears two phase 3 trials

pharmaphorum

GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company says new IL-5 inhibitor depemokimab (formerly GSK3511294) has the potential to become the first ultra-long-acting biologic for severe asthma with a six-monthly dosing schedule.

104
104
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

New NIH findings on talc use and ovarian cancer pose challenge to J&J's high-stakes defense

Fierce Pharma

The more than 53,000 women in the U.S. | The more than 53,000 women in the U.S. who have filed injury lawsuits against Johnson & Johnson have added ammunition for their claims as new research indicates there is an association between long-term use of talcum-based powders and an increased risk of developing ovarian cancer.

290
290
article thumbnail

Tony Blair Institute weighs in on use of NHS patient data

pharmaphorum

A think tank set up by former UK Prime Minister Tony Blair has called for the formation of a public-private trust that could oversee the sharing of anonymised patient data with trusted researchers.

Patients 103

More Trending

article thumbnail

What Frustrates 3 Women’s Health Execs

MedCity News

There have been several advancements in the women’s health space, but we still have a long way to go, execs said during a recent panel. The post What Frustrates 3 Women’s Health Execs appeared first on MedCity News.

98
article thumbnail

Bristol Myers lines up Opdivo treatment in Pakistan, Rwanda and beyond as part of 10-year access campaign

Fierce Pharma

When it comes to supporting cancer care and other therapeutic approaches in low- and middle-income countries (LMICs), Bristol Myers Squibb is taking a long-term view. | In its quest to reach more than 200,000 patients with its medicines in low- and middle-income countries by 2033, BMS is embarking on a 10-year access effort.

Medicine 250
article thumbnail

Bristol Myers Squibb Plans 10-Year Strategy to Expand Access to Medications

PharmaTech

The company is collaborating with the Access to Oncology Medicines Coalition to expand patient access to immuno-oncology therapy Opdivo.

Medical 111
article thumbnail

Merck KGaA unit avoids DOJ prosecution after exposing scheme to divert drugs to China

Fierce Pharma

Merck KGaA’s North American life science division, MilliporeSigma, has made U.S. | The U.S. Department of Justice on Wednesday announced that Florida residents Pen Yu, 51, and Gregory Muñoz, 45, each pleaded guilty to one count of wire fraud conspiracy for their roles in a scheme to “fraudulently procure deeply discounted products” from Merck KGaA's MilliporeSigma and export them to China using faked export documents.

245
245
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

No nitrosamines: How parenteral packaging is evolving to meet today’s E&L challenges

Pharmaceutical Technology

As the nitrosamine scandal continues, we explore the advancements in parenteral packaging materials that are reducing the risk of this contaminant in modern injectables.

97
article thumbnail

Sanofi, Bristol Myers on the hook for $916M in do-over of Plavix marketing case in Hawaii

Fierce Pharma

Hawaii has ordered BMS and Sanofi to pay a $916M for failing to warn about the potential ineffectiveness of blood thinner Plavix in some patients.

Marketing 238
article thumbnail

Allying With Patients to Make Every Cure Possible

MedCity News

To win the battle against rare diseases, drug developers must work hand-in-hand with patients. The post Allying With Patients to Make Every Cure Possible appeared first on MedCity News.

article thumbnail

US senators accuse pharma firms of abusing patent system

pharmaphorum

Lawmakers across the political divide have accused the pharma industry of abusing the patent system to keep the prices of their products as high as possible.

Pharma 99
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Biogen Immunology Strategy Comes Into Focus With $1B HI-Bio Acquisition

MedCity News

Biogen’s acquisition of Human Immunology Biosciences brings a drug candidate with potential applications in multiple immune-mediated disorders. The deal comes just prior to the scheduled presentation of clinical data in two of them. The post Biogen Immunology Strategy Comes Into Focus With $1B HI-Bio Acquisition appeared first on MedCity News.

article thumbnail

Click buys Better assets to speed its digital obesity drive

pharmaphorum

Digital health firm Click Therapeutics has bought the assets of Better Therapeutics to speed up development of a prescription digital therapeutic for obesity

article thumbnail

European Commission grants first-of-a-kind biosimilar approval

European Pharmaceutical Review

The European Commission (EC) has approved the first and only biosimilar versions of the reference medicines Xgeva ® and Prolia ® in Europe. Sandoz shared that Wyost ® (denosumab) is approved for treating cancer-related bone disease. Jubbonti ® (denosumab) is authorised as an osteoporosis treatment. The decision by the EC “is a major step in advancing the Sandoz growth strategy”, the company asserted.

article thumbnail

Immune checkpoint enhancer biotech AltruBio raises $225m

pharmaphorum

Immune checkpoint enhancer biotech AltruBio raises $225m to support phase 2 trials of its PSGL-1-targeted drug for ulcerative colitis

94
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

New ‘plug and play’ system to offer novel way of delivering vaccines and treatments

PharmaTimes

The nanocage technology combines both mRNA and traditional virus-based vaccines to create virus-like efficacious vaccines

84
article thumbnail

European authorities recognised for leading medicine regulatory oversight

European Pharmaceutical Review

A total of 33 regulatory authorities have been granted designation as World Health Organization ( WHO ) Listed Authorities under the WLA framework. The agencies holding this status have been approved and validated as compliant and committed to upholding the “highest level of regulatory standards and practices for quality, safety and efficacy of medicines and vaccines ”.

article thumbnail

[Podcast] Is Your Healthcare Email Marketing HIPAA Compliant?

Healthcare Success

Is your email marketing HIPAA compliant? Do you have adequate encryption at every step? Are you sure? Remember, even a patient’s email address could be considered PHI if linked to a health condition or treatment. If you are suddenly feeling a little uneasy, I promise you are not alone. Most healthcare marketers are unaware that seemingly innocuous patient email marketing campaigns are yet another area where you could inadvertently run afoul with HIPAA regulations, or, even worse, suffer a breach

article thumbnail

UK lung cancer study demonstrates further evidence on importance of CT screening

PharmaTimes

Currently the third most common cancer in the UK, lung cancer affects 40,000 people annually

92
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Judge says Ultragenyx must face Henrietta Lacks estate suit

pharmaphorum

An attempt by Ultragenyx to have a lawsuit filed by the family of Henrietta Lacks dismissed before it could be heard has failed. US District Judge Deborah Boardman turned down Ultragenyx’s request in a Baltimore federal court, concluding that the allegation that the company had profited from cells harvested from Lacks without her consent should be held up to scrutiny.

62
article thumbnail

Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work?

PharmaVoice

Direct-to-consumer platforms offer consumers an online path to sourcing popular medications, but some therapeutic areas may be better suited for the business model.

article thumbnail

Pharma Pulse 5/22/24: A Pharmacist’s Impact on Inclusive Health Care, ChatGPT Usage to Support Drug Development & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 104
article thumbnail

Mission Critical: Society Publishing in an Open Access World

Copyright Clearance Center

The post Mission Critical: Society Publishing in an Open Access World appeared first on Copyright Clearance Center.

75
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Drug shortages, cost concerns and iffy access — how DTC and telehealth could even the playing field

PharmaVoice

Companies like UpScriptHealth led the charge with online prescriptions decades ago, and now the industry is catching on to solve some of healthcare’s most pressing issues.

article thumbnail

Eurofins BPT expands its US environmental monitoring onsite collection & testing footprint

PharmaTech

EBPT provides expert support for Environmental Monitoring programs, ensuring clean and controlled manufacturing environments. Our services include designing monitoring programs, collecting samples, and analyzing data using advanced equipment. With locations across the U.S., EBPT offers nationwide support to pharmaceutical and medical device clients with standardized practices and specialized expertise.

article thumbnail

US Pharma and Biotech Summit 2024: Bringing the Skillset of Generation Alpha to the Pharma Industry

PharmExec

In an interview with Pharm Exec Associate Editor Don Tracy, Carmen Villar, VP, ESG & Corporate Citizenship, Gilead Sciences discusses new skills that members of generation Alpha will bring to the pharma industry and potential struggles that they may face.

Pharma 52
article thumbnail

Eurofins BPT Cell Banking certified by global regulatory agencies

PharmaTech

Eurofins BioPharma Product Testing in Lancaster, PA, is a leader in ensuring the quality and safety of cell banks used in biomanufacturing. Certified by regulatory agencies like the FDA and TGA, EBPT's Cell Banking Department operates under stringent quality standards. We employ controlled processes, including employee training and contamination control, to maintain quality.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.